Healthcare Services

Neurological Biomarkers Market Size Forecast To Achieve $22.81 Billion By 2030 With 14% CAGR

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Rise In Market Size Of The Neurological Biomarkers Market During The Forecast Period?

The neurological biomarkers market has experienced rapid expansion in recent years. Projections indicate it will grow from $11.92 billion in 2025 to $13.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.4%. Historically, this growth can be attributed to the rising prevalence of neurological disorders, the early development of protein biomarkers, increased utilization of imaging biomarkers, growing adoption of DNA biomarkers, and the initial integration of biomarkers in clinical trials.

The neurological biomarkers market size is projected to experience swift expansion in the upcoming years. It is forecast to reach $22.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.0%. This anticipated growth is due to several factors, including the expanding utilization of personalized medicine based on biomarkers, a growing need for metabolomics biomarkers, increased funding for central nervous system (CNS) drug development, the emergence of advanced diagnostic platforms, and the expanding use of biomarker-guided disease monitoring. Key trends anticipated during this period encompass the increasing application of biomarkers in early detection of neurological conditions, a wider acceptance of proteomic and genomic biomarkers, the broader deployment of imaging biomarkers for CNS disorder assessment, a heightened demand for biomarkers in pharmaceutical development pathways, and an increasing clinical emphasis on testing biomarkers for neurodegenerative diseases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

Which Drivers Are Advancing The Neurological Biomarkers Market Growth?

The neurological biomarker market is projected to grow due to the increasing occurrence of neurological diseases. These conditions affect the brain, spinal cord, and all other body nerves, with Parkinson’s disease being an example of a neurodegenerative disorder impacting the neurological system and nerve-controlled areas. Neurological biomarkers assist in providing an early diagnosis for Parkinson’s disease via pathological, biochemical, and genetic testing. For instance, in October 2023, the World Federation of Neurology, a UK-based charity, reported that neurological disorders now stand as the second-leading cause of death and the primary cause of disability worldwide, affecting over 40 percent of the global population in 2023, and the number of individuals with brain disease is projected to nearly double by 2050, reflecting an accelerating global health burden. Thus, the escalating prevalence of neurological diseases is driving the expansion of the neurological biomarker market.

How Is The Neurological Biomarkers Market Distributed Across Key Segments?

The neurological biomarkers market covered in this report is segmented –

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products

2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy

3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users

Subsegments:

1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers

2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers

3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers

4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers

5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers

What Trends Are Influencing The Future Of The Neurological Biomarkers Market?

Leading companies in the neurogenomics market are concentrating on developing sophisticated solutions, such as whole genome sequencing platforms, to improve the diagnosis and understanding of complex neurological disorders. Whole genome sequencing platforms are tools used to analyze the complete DNA sequence of an individual’s genome, assisting in the identification of genetic factors linked to neurological conditions. For instance, in April 2023, Centogene N.V., a Germany-based company involved in the diagnosis and research of rare diseases, launched CentoGenome, which is presented as the world’s most comprehensive whole-genome sequencing (WGS) solution for diagnosing rare and neurodegenerative diseases. This platform utilizes PCR-free technology to facilitate high-quality, unbiased sequencing across intricate genetic regions. It enhances variant detection using an advanced bioinformatics pipeline and expert interpretation, identifying almost all disease-causing variants in a single test. Additionally, it offers integrated, lifelong diagnostic support, including free variant reclassification and confirmatory testing as new scientific knowledge becomes available.

Which Key Players Are Active In The Neurological Biomarkers Market?

Major companies operating in the neurological biomarkers market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Access The Complete Neurological Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Which Region Accounts For The Highest Share Of The Neurological Biomarkers Market?

North America was the largest region in the neurological biomarkers market in 2025. The regions covered in the neurological biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurological Biomarkers Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12677&type=smp

Browse Through More Reports Similar to the Global Neurological Biomarkers Market 2026, By The Business Research Company

Genomics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Neurological Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Neuroscience Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795